Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02034110 : Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
PhasePhase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Signed, written informed consent.

- Sex: male or female.

- Age: >=18 years of age at the time of providing informed consent.

- Eastern Cooperative Oncology Group (ECOG) performance status: 0, 1 or 2.

- BRAF V600E mutation-positive tumor: Local testing - Local BRAF mutation test results
obtained by a Clinical Laboratory Improvement Amendments (CLIA) approved local
laboratory may be used to permit enrollment of subjects with positive results. Local
BRAF mutation test results will be subject to central verification; Central testing -
Local BRAF mutation test results will be confirmed by central testing in a CLIA
approved, designated central reference laboratory by the THxID BRAF assay or an
alternate GSK designated assay. NOTE: For central testing, Formalin-fixed
paraffin-embedded (FFPE) core bone marrow (BM) biopsies are not acceptable from
subjects in the Multiple myeloma (MM) cohort.

- Able to swallow and retain orally administered medication. NOTE: Subject should not
have any clinically significant gastrointestinal (GI) abnormalities that may alter
absorption such as malabsorption syndrome or major resection of the stomach or
bowels. For example, subjects should have no more than 50% of the large intestine
removed and no sign of malabsorption (i.e., diarrhea).NOTE: If clarification is
needed as to whether a condition will significantly affect the absorption of study
treatments, contact the GSK Medical Monitor.

- Female Subjects of Childbearing Potential: Subjects must have a negative serum
pregnancy test within 7 days prior to the first dose of study treatment and agrees to
use effective contraception, throughout the treatment period and for 4 months after
the last dose of study treatment.

- French subjects: In France, a subject will be eligible for inclusion in this study
only if either affiliated to or a beneficiary of a social security category.

Exclusion Criteria:

- Prior treatment with: BRAF and/or MEK inhibitor(s); anti-cancer therapy (e.g.,
chemotherapy with delayed toxicity, immunotherapy, biologic therapy or
chemoradiation) within 21 days (or within 42 days if prior nitrosourea or mitomycin C
containing therapy) prior to enrollment and/or daily or weekly chemotherapy without
the potential for delayed toxicity within 14 days prior to enrolment; Investigational
drug(s) within 30 days or 5 half-lives, whichever is longer, prior to enrollment

- Previous major surgery within 21 days prior to enrollment.

- Prior extensive radiotherapy treatment within 21 days prior to enrolment. NOTE:
Limited radiotherapy for palliative care is permitted within 14 days prior to
enrollment as long as any radiation-related toxicity has resolved prior to

- Prior solid organ transplantation or allogenic stem cell transplantation (ASCT).
NOTE: Previous autologous bone marrow transplant (ABMT) or autologous peripheral
blood stem cell transplant (PBSCT) is permitted.

- History of: Interstitial lung disease or pneumonitis; Another malignancy. NOTE:
Subjects with another malignancy are eligible if: (a) disease-free for 3 years, (b)
had a history of completely resected non-melanoma skin cancer, and/or (c) have a
indolent second malignancy(ies) defined as a slow growing second/concurrent
malignancy which is characterized by slow growth, a high initial response rate and a
relapsing , progressive disease course. For example, a previously untreated low grade
and select intermediate-grade lymphoid malignancy would be allowed as per the
available body of evidence. There are no available clinical alternatives to the
proposed population. Consult a GSK Medical Monitor if unsure whether second
malignancies meet requirements specified above.

- Presence of: cerebral metastases (except for subjects in the WHO Grade 1 or 2 Glioma
or WHO Grade 3 or 4 Glioma histology cohorts). NOTE: Subjects with brain metastases
may be included if: All known lesions have been previously treated with surgery or
stereotactic radiosurgery, and Any remaining cerebral lesion(s) are asymptomatic and
confirmed stable disease (i.e., no increase in lesion size) for >=90 days prior to
enrollment as documented by two consecutive magnetic resonance imaging (MRI) or
computed tomography (CT) scans with contrast, and No treatment with corticosteroids
or enzyme-inducing anticonvulsants required for >=30 days prior to enrolment.
Approval received from GSK Medical Monitor.

- Presence of symptomatic or untreated leptomeningeal or spinal cord compression. NOTE:
Subjects who have been previously treated for these conditions and have stable
central nervous system (CNS) disease (documented by consecutive imaging studies) for
>60 days, are asymptomatic and currently not taking corticosteroids, or have been on
a stable dose of corticosteroids for at least 30 days prior to enrollment, are

- Presence of pre-existing >= Grade 2 peripheral neuropathy.

- Presence of unresolved treatment-related toxicity of >= Grade 2 (except alopecia) or
toxicities listed in the general and histology-specific adequate organ function
tables at the time of enrolment.

- Presence of any serious and/or unstable pre-existing medical disorder (aside from
malignancy exception above), psychiatric disorder, or other conditions that could
interfere with subject's safety, obtaining informed consent or compliance to the
study procedures.

- History or current evidence/risk of retinal vein occlusion (RVO) or central serous
retinopathy (CSR): History of RVO or CSR, or predisposing factors to RVO or CSR
(e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled systemic disease
such as hypertension or diabetes mellitus, or history of hyperviscosity or
hypercoagulability syndromes); Visible retinal pathology as assessed by ophthalmic
examination that is considered a risk factor for RVO or CSR such as evidence of new
optic disc cupping, evidence of new visual field defects and intraocular pressure >21

- History or evidence of cardiovascular risk including any of the following: Acute
coronary syndromes (including myocardial infarction and unstable angina), coronary
angioplasty, or stenting within 6 months prior to enrolment; Clinically significant
uncontrolled arrhythmias NOTE: Subjects with controlled atrial fibrillation for >30
days prior to enrollment are eligible; Class II or higher congestive heart failure as
defined by the New York Heart Association (NYHA) criteria; Left ventricular ejection
fraction (LVEF) below the institutional lower limit of normal (LLN). NOTE: If a LLN
does not exist at an institution, then use LVEF <50%.; Corrected QT (QTc) interval
for heart rate using Bazett-corrected QT interval (QTcB) >=480 millisecond (msec);
Intracardiac defibrillator and/or permanent pacemaker; Treatment-refractory
hypertension defined as a blood pressure (BP) >140/90 millimeters of mercury (mmHg)
which may not be controlled by anti-hypertensive medication(s) and/or lifestyle
modifications; Known cardiac metastases.

- Current use of prohibited medication(s) or requirement of prohibited medications
during study. NOTE: Use of anticoagulants such as warfarin is permitted; however,
international normalization ratio (INR) must be monitored according with local
institutional practice.

- Positive for: Hepatitis B surface antigen or Hepatitis C antibody. NOTE: Subjects
with laboratory evidence of cleared hepatitis B virus (HBV) and hepatitis C virus
(HCV) infection will be permitted. NOTE: False positive subjects may be cleared for
enrollment based on RNA-based assays; Human immunodeficiency virus (HIV); testing not

- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to study treatment, or excipients, or to dimethyl sulfoxide and/or
sulfonamides (structural component of dabrafenib).

- Female subjects: Pregnant, lactating or actively breastfeeding.

- Subjects enrolled in France: The French subject has participated in any study using
an investigational product (IP) within 30 days prior to enrollment in this study.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557